|
1
|
Klein AP: Pancreatic cancer epidemiology:
Understanding the role of lifestyle and inherited risk factors. Nat
Rev Gastroenterol Hepatol. 18:493–502. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan C, Kim J, Wang QL, Lee AA and Babic
A: PanScan/PanC4 I-III Consortium; Amundadottir LT, Klein AP, Li D,
McCullough ML, et al: The age-dependent association of risk factors
with pancreatic cancer. Ann Oncol. 33:693–701. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yeo TP: Demographics, epidemiology, and
inheritance of pancreatic ductal adenocarcinoma. Semin Oncol.
42:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martini G, Dienstmann R, Ros J, Baraibar
I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G,
Tabernero J and Elez E: Molecular subtypes and the evolution of
treatment management in metastatic colorectal cancer. Ther Adv Med
Oncol. 12:17588359209360892020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whatcott CJ, Han H and Von Hoff DD: The
role of the tumor microenvironment in resistance to therapy in
pancreatic cancer. Br J Cancer. 112(Suppl 1): S9–S15. 2015.
|
|
8
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar
|
|
9
|
Gaianigo N, Melisi D and Carbone C: EMT
and treatment resistance in pancreatic cancer. Cancers (Basel). 9.
pp. 1222017, View Article : Google Scholar
|
|
10
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao W, Zhou J, Deng Z, Gao Y and Cheng Y:
SPOP promotes tumor progression via activation of β-catenin/TCF4
complex in clear cell renal cell carcinoma. Int J Oncol.
49:1001–1008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aiello NM, Maddipati R, Norgard RJ, Balli
D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, et al:
EMT subtype influences epithelial plasticity and mode of cell
migration. Dev Cell. 45681–695. (e4)2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu
Y, Yao Y and Li D: The epithelial to mesenchymal transition (EMT)
and cancer stem cells: Implication for treatment resistance in
pancreatic cancer. Mol Cancer. 16:522017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Venhuizen JH, Jacobs FJC, Span PN and
Zegers MM: P120 and E-cadherin: Double-edged swords in tumor
metastasis. Semin Cancer Biol. 60:107–120. 2020. View Article : Google Scholar
|
|
16
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sánchez-Tilló E, Lázaro A, Torrent R,
Cuatrecasas M, Vaquero EC, Castells A, Engel P and Postigo A: ZEB1
represses E-cadherin and induces an EMT by recruiting the SWI/SNF
chromatin-remodeling protein BRG1. Oncogene. 29:3490–3500. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nowak E and Bednarek I: Aspects of the
epigenetic regulation of EMT related to cancer metastasis. Cells.
10:34352021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang YE and Stuelten CH: Alternative
splicing in EMT and TGF-β signaling during cancer progression.
Semin Cancer Biol. 101:1–11. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chastney MR, Kaivola J, Leppänen VM and
Ivaska J: The role and regulation of integrins in cell migration
and invasion. Nat Rev Mol Cell Biol. 26:147–167. 2025. View Article : Google Scholar
|
|
23
|
Hosseini K, Taubenberger A, Werner C and
Fischer-Friedrich E: EMT-induced Cell-mechanical changes enhance
mitotic rounding strength. Adv Sci (Weinh). 7. pp. 20012762020,
View Article : Google Scholar
|
|
24
|
Zhu Y, Herndon JM, Sojka DK, Kim KW,
Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, et
al: Tissue-resident macrophages in pancreatic ductal adenocarcinoma
originate from embryonic hematopoiesis and promote tumor
progression. Immunity. 47323–338. (e6)2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quemerais C, Jean C, Brunel A, Decaup E,
Labrousse G, Audureau H, Raffenne J, Belhabib I, Cros J, Perraud A,
et al: Unveiling FKBP7 as an early endoplasmic reticulum sentinel
in pancreatic stellate cell activation, collagen remodeling and
tumor progression. Cancer Lett. 614:2175382025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akhmetkaliyev A, Alibrahim N, Shafiee D
and Tulchinsky E: EMT/MET plasticity in cancer and Go-or-Grow
decisions in quiescence: The two sides of the same coin? Mol
Cancer. 22:902023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niland S, Riscanevo AX and Eble JA: Matrix
metalloproteinases shape the tumor microenvironment in cancer
progression. Int J Mol Sci. 23:1462021. View Article : Google Scholar
|
|
28
|
Strouhalova K, Tolde O, Rosel D and Brábek
J: Cytoplasmic Tail of MT1-MMP: A Hub of MT1-MMP Regulation and
Function. Int J Mol Sci. 24:50682023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tao X, Xiang H, Pan Y, Shang D, Guo J, Gao
G and Xiao GG: Pancreatitis initiated pancreatic ductal
adenocarcinoma: Pathophysiology explaining clinical evidence.
Pharmacol Res. 168:1055952021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sarkar R, Xu Z, Perera CJ and Apte MV:
Emerging role of pancreatic stellate cell-derived extracellular
vesicles in pancreatic cancer. Semin Cancer Biol. 93:114–122. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng D, Fu M, Wang M, Wei Y and Wei X:
Targeting TGF-β signal transduction for fibrosis and cancer
therapy. Mol Cancer. 21:1042022. View Article : Google Scholar
|
|
32
|
Li J, Chen X, Kang R, Zeh H, Klionsky DJ
and Tang D: Regulation and function of autophagy in pancreatic
cancer. Autophagy. 17:3275–3296. 2021. View Article : Google Scholar :
|
|
33
|
Lin D, Shen L, Luo M, Zhang K, Li J, Yang
Q, Zhu F, Zhou D, Zheng S, Chen Y and Zhou J: Circulating tumor
cells: Biology and clinical significance. Signal Transduct Target
Ther. 6:4042021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haber DA and Velculescu VE: Blood-based
analyses of cancer: Circulating tumor cells and circulating tumor
DNA. Cancer Discov. 4:650–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lawrence R, Watters M, Davies CR, Pantel K
and Lu YJ: Circulating tumour cells for early detection of
clinically relevant cancer. Nat Rev Clin Oncol. 20:487–500. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mullins RDZ, Pal A, Barrett TF, Heft Neal
ME and Puram SV: Epithelial-mesenchymal plasticity in tumor immune
evasion. Cancer Res. 82:2329–2343. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hariri A, Mirian M, Khosravi A, Zarepour
A, Iravani S and Zarrabi A: Intersecting pathways: The role of
hybrid E/M cells and circulating tumor cells in cancer metastasis
and drug resistance. Drug Resist Updat. 76:1011192024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jolly MK, Somarelli JA, Sheth M, Biddle A,
Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A and
Levine H: Hybrid epithelial/mesenchymal phenotypes promote
metastasis and therapy resistance across carcinomas. Pharmacol
Ther. 194:161–184. 2019. View Article : Google Scholar
|
|
39
|
Bustamante A, Baritaki S, Zaravinos A and
Bonavida B: Relationship of signaling pathways between RKIP
expression and the inhibition of EMT-inducing transcription factors
SNAIL1/2, TWIST1/2 and ZEB1/2. Cancers (Basel). 16:31802024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vidlarova M, Rehulkova A, Stejskal P,
Prokopova A, Slavik H, Hajduch M and Srovnal J: Recent advances in
methods for circulating tumor cell detection. Int J Mol Sci.
24:39022023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Padmanaban V, Krol I, Suhail Y, Szczerba
BM, Aceto N, Bader JS and Ewald AJ: E-cadherin is required for
metastasis in multiple models of breast cancer. Nature.
573:439–444. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ward MP, E Kane L, A Norris L, Mohamed BM,
Kelly T, Bates M, Clarke A, Brady N, Martin CM, Brooks RD, et al:
Platelets, immune cells and the coagulation cascade; friend or foe
of the circulating tumour cell? Mol Cancer. 20:592021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leblanc R and Peyruchaud O: Metastasis:
New functional implications of platelets and megakaryocytes. Blood.
128:24–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tao J, Zhu L, Yakoub M, Reißfelder C,
Loges S and Schölch S: Cell-Cell interactions drive metastasis of
circulating tumor microemboli. Cancer Res. 82:2661–2671. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou J, Yang S, Zhu D, Li H, Miao X, Gu M,
Xu W, Zhang Y, Tang W, Shen R, et al: The crosstalk between anoikis
and epithelial-mesenchymal transition and their synergistic roles
in predicting prognosis in colon adenocarcinoma. Front Oncol.
13:11842152023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cao Z, Livas T and Kyprianou N: Anoikis
and EMT: Lethal 'Liaisons' during Cancer Progression. Crit Rev
Oncog. 21:155–168. 2016. View Article : Google Scholar
|
|
47
|
Schuster E, Taftaf R, Reduzzi C, Albert
MK, Romero-Calvo I and Liu H: Better together: Circulating tumor
cell clustering in metastatic cancer. Trends Cancer. 7:1020–1032.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Costa C, Muinelo-Romay L, Cebey-López V,
Pereira-Veiga T, Martínez-Pena I, Abreu M, Abalo A, Lago-Lestón RM,
Abuín C, Palacios P, et al: Analysis of a Real-world cohort of
metastatic breast cancer patients shows circulating tumor cell
clusters (CTC-clusters) as predictors of patient outcomes. Cancers
(Basel). 12:11112020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li
LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates
breast cancer cell plasticity during EMT and MET plasticity by
differentially sponging miR-200b/c and let-7b. Sci Signal.
10:eaak95572017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alečković M, McAllister SS and Polyak K:
Metastasis as a systemic disease: Molecular insights and clinical
implications. Biochim Biophys Acta Rev Cancer. 1872:89–102. 2019.
View Article : Google Scholar
|
|
51
|
Shen S, Vagner S and Robert C: Persistent
cancer cells: The deadly survivors. Cell. 183:860–874. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gerstberger S, Jiang Q and Ganesh K:
Metastasis. Cell. 186:1564–1579. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Massagué J and Obenauf AC: Metastatic
colonization by circulating tumour cells. Nature. 529:298–306.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Costa-Silva B, Aiello NM, Ocean AJ, Singh
S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et
al: Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 17:816–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lin Z, Li G, Jiang K, Li Z and Liu T:
Cancer therapy resistance mediated by cancer-associated
fibroblast-derived extracellular vesicles: Biological mechanisms to
clinical significance and implications. Mol Cancer. 23:1912024.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang X, Eichhorn PJA and Thiery JP: TGF-β,
EMT, and resistance to anti-cancer treatment. Semin Cancer Biol.
97:1–11. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chu X, Tian W, Ning J, Xiao G, Zhou Y,
Wang Z, Zhai Z, Tanzhu G, Yang J and Zhou R: Cancer stem cells:
Advances in knowledge and implications for cancer therapy. Signal
Transduct Target Ther. 9:1702024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bayik D and Lathia JD: Cancer stem
cell-immune cell crosstalk in tumour progression. Nat Rev Cancer.
21:526–536. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chang CH and Pauklin S: ROS and TGFβ: From
pancreatic tumour growth to metastasis. J Exp Clin Cancer Res.
40:1522021. View Article : Google Scholar
|
|
61
|
Stoica AF, Chang CH and Pauklin S:
Molecular therapeutics of pancreatic ductal adenocarcinoma:
Targeted pathways and the role of cancer stem cells. Trends
Pharmacol Sci. 41:977–993. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Modi SJ and Kulkarni VM: Discovery of
VEGFR-2 inhibitors exerting significant anticancer activity against
CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β
induced epithelial-mesenchymal transition (EMT) in hepatocellular
carcinoma. Eur J Med Chem. 207:1128512020. View Article : Google Scholar
|
|
63
|
Krebs AM, Mitschke J, Lasierra Losada M,
Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D,
Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key
factor for cell plasticity and promotes metastasis in pancreatic
cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Feng J, Hu S, Liu K, Sun G and Zhang Y:
The role of MicroRNA in the regulation of tumor
Epithelial-mesenchymal transition. Cells. 11:19812022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bracken CP, Goodall GJ and Gregory PA: RNA
regulatory mechanisms controlling TGF-β signaling and EMT in
cancer. Semin Cancer Biol. 102-103:4–16. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sangrador I, Molero X, Campbell F,
Franch-Expósito S, Rovira-Rigau M, Samper E, Domínguez-Fraile M,
Fillat C, Castells A and Vaquero EC: Zeb1 in stromal myofibroblasts
promotes Kras-driven development of pancreatic cancer. Cancer Res.
78:2624–2637. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Duan H, Liu Y, Gao Z and Huang W: Recent
advances in drug delivery systems for targeting cancer stem cells.
Acta Pharm Sin B. 11:55–70. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pan G, Liu Y, Shang L, Zhou F and Yang S:
EMT-associated microRNAs and their roles in cancer stemness and
drug resistance. Cancer Commun (Lond). 41:199–217. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Brabletz S, Schuhwerk H, Brabletz T and
Stemmler MP: Dynamic EMT: A multi-tool for tumor progression. EMBO
J. 4:e1086472021. View Article : Google Scholar
|
|
70
|
Funamizu N, Honjo M, Tamura K, Sakamoto K,
Ogawa K and Takada Y: microRNAs associated with gemcitabine
resistance via EMT, TME, and drug metabolism in pancreatic cancer.
Cancers (Basel). 15. pp. 12302023, View Article : Google Scholar
|
|
71
|
Redfern AD, Spalding LJ and Thompson EW:
The Kraken Wakes: Induced EMT as a driver of tumour aggression and
poor outcome. Clin Exp Metastasis. 35:285–308. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Singh A and Settleman J: EMT, Cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bulle A and Lim KH: Beyond just a tight
fortress: Contribution of stroma to epithelial-mesenchymal
transition in pancreatic cancer. Signal Transduct Target Ther.
5:2492020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Joshi VB, Gutierrez Ruiz OL and Razidlo
GL: The cell biology of metastatic invasion in pancreatic cancer:
Updates and mechanistic insights. Cancers (Basel). 15. pp.
21692023, View Article : Google Scholar
|
|
76
|
Youssef KK and Nieto MA:
Epithelial-mesenchymal transition in tissue repair and
degeneration. Nat Rev Mol Cell Biol. 25:720–739. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bracken CP and Goodall GJ: The many
regulators of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 23:89–90. 2022. View Article : Google Scholar
|
|
78
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Debnath P, Huirem RS, Dutta P and
Palchaudhuri S: Epithelial-mesenchymal transition and its
transcription factors. Biosci Rep. 42:BSR202117542022. View Article : Google Scholar :
|
|
80
|
Sheng W, Tang J, Cao R, Shi X, Ma Y and
Dong M: Numb-PRRL promotes TGF-β1- and EGF-induced
epithelial-to-mesenchymal transition in pancreatic cancer. Cell
Death Dis. 13:1732022. View Article : Google Scholar
|
|
81
|
Shao M, Wang L, Zhang Q, Wang T and Wang
S: STMN2 overexpression promotes cell proliferation and EMT in
pancreatic cancer mediated by WNT/β-catenin signaling. Cancer Gene
Ther. 30:472–480. 2023.
|
|
82
|
Zhao R, Yi Y, Liu H, Xu J, Chen S, Wu D,
Wang L and Li F: RHOF promotes Snail1 lactylation by enhancing
PKM2-mediated glycolysis to induce pancreatic cancer cell
endothelial-mesenchymal transition. Cancer Metab. 12:322024.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tang Y, Tang Y and Cheng YS: miR-34a
inhibits pancreatic cancer progression through Snail1-mediated
epithelial-mesenchymal transition and the Notch signaling pathway.
Sci Rep. 7:382322017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tang L, Ji M, Liang X, Chen D, Liu A, Yang
G, Shi L, Fu Z and Shao C: Downregulated F-Box/LRR-Repeat protein 7
facilitates pancreatic cancer metastasis by regulating snail1 for
proteasomal degradation. Front Genet. 12:6500902021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lambies G, Miceli M, Martínez-Guillamon C,
Olivera-Salguero R, Peña R, Frías CP, Calderó I, Atanassov BS, Dent
SYR, Arribas J, et al: TGFβ-Activated USP27X Deubiquitinase
regulates cell migration and chemoresistance via stabilization of
snail1. Cancer Res. 79:33–46. 2019. View Article : Google Scholar
|
|
86
|
García de Herreros A: Control of snail1
protein stability by post-translational modifications: The basis
for a complex regulation of Snail1 function. Int J Biol Sci.
21:3183–3196. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Fendrich V, Jendryschek F, Beeck S, Albers
M, Lauth M, Esni F, Heeger K, Dengler J, Slater EP, Holler JPN, et
al: Genetic and pharmacologic abrogation of Snail1 inhibits
acinar-to-ductal metaplasia in precursor lesions of pancreatic
ductal adenocarcinoma and pancreatic injury. Oncogene.
37:1845–1856. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Frey P, Devisme A, Schrempp M, Andrieux G,
Boerries M and Hecht A: Canonical BMP signaling executes
epithelial-mesenchymal transition downstream of SNAIL1. Cancers
(Basel). 12. pp. 10192020, View Article : Google Scholar
|
|
89
|
Ma J, Zhang J, Weng YC and Wang JC:
EZH2-Mediated microRNA-139-5p Regulates Epithelial-mesenchymal
transition and lymph node metastasis of pancreatic cancer. Mol
Cells. 41:868–880. 2018.PubMed/NCBI
|
|
90
|
Funamizu N, Hu C, Lacy C, Schetter A,
Zhang G, He P, Gaedcke J, Ghadimi MB and Ried T: Macrophage
migration inhibitory factor induces epithelial to mesenchymal
transition, enhances tumor aggressiveness and predicts clinical
outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer.
132:785–794. 2013. View Article : Google Scholar
|
|
91
|
Mirzaei S, Saghari S, Bassiri F, Raesi R,
Zarrabi A, Hushmandi K, Sethi G and Tergaonkar V: NF-κB as a
regulator of cancer metastasis and therapy response: A focus on
epithelial-mesenchymal transition. J Cell Physiol. 237:2770–2795.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhang Y, Xue X, Zhao X, Qin L, Shen Y, Dou
H, Sun J, Wang T and Yang DQ: Vasohibin 2 promotes malignant
behaviors of pancreatic cancer cells by inducing
epithelial-mesenchymal transition via Hedgehog signaling pathway.
Cancer Med. 7:5567–5576. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Eguchi T, Csizmadia E, Kawai H, Sheta M,
Yoshida K, Prince TL, Wegiel B and Calderwood SK: SCAND1 reverses
Epithelial-to-mesenchymal transition (EMT) and suppresses prostate
cancer growth and migration. Cells. 11:39932022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Saitoh M: Transcriptional regulation of
EMT transcription factors in cancer. Semin Cancer Biol. 97:21–29.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ghafoor S, Garcia E, Jay DJ and Persad S:
Molecular mechanisms regulating epithelial mesenchymal transition
(EMT) to promote cancer progression. Int J Mol Sci. 26:43642025.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chen S, Chen JZ, Zhang JQ, Chen HX, Yan
ML, Huang L, Tian YF, Chen YL and Wang YD: Hypoxia induces
TWIST-activated epithelial-mesenchymal transition and proliferation
of pancreatic cancer cells in vitro and in nude mice. Cancer Lett.
383:73–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang J, Nikhil K, Viccaro K, Chang L,
Jacobsen M, Sandusky G and Shah K: The Aurora-A-Twist1 axis
promotes highly aggressive phenotypes in pancreatic carcinoma. J
Cell Sci. 130:1078–1093. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ji H, Lu HW, Li YM, Lu L, Wang JL, Zhang
YF and Shang H: Twist promotes invasion and cisplatin resistance in
pancreatic cancer cells through growth differentiation factor 15.
Mol Med Rep. 12:3841–3848. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yang J, Zhang X, Zhang Y, Zhu D, Zhang L,
Li Y, Zhu Y, Li D and Zhou J: HIF-2α promotes
epithelial-mesenchymal transition through regulating Twist2 binding
to the promoter of E-cadherin in pancreatic cancer. J Exp Clin
Cancer Res. 35:262016. View Article : Google Scholar
|
|
100
|
Wang H, Li QF, Chow HY, Choi SC and Leung
YC: Arginine deprivation inhibits pancreatic cancer cell migration,
invasion and EMT via the down regulation of Snail, Slug, Twist, and
MMP1/9. J Physiol Biochem. 76:73–83. 2020. View Article : Google Scholar
|
|
101
|
Yu H, Gao G, Cai J, Song H, Ma Z, Jin X,
Ji W and Pan B: MiR-539 functions as a tumor suppressor in
pancreatic cancer by targeting TWIST1. Exp Mol Pathol. 108:143–149.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wong CH, Lou UK, Fung FK, Tong JHM, Zhang
CH, To KF, Chan SL and Chen Y: CircRTN4 promotes pancreatic cancer
progression through a novel CircRNA-miRNA-lncRNA pathway and
stabilizing epithelial-mesenchymal transition protein. Mol Cancer.
21:102022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Katoch A, Jamwal VL, Faheem MM, Kumar S,
Senapati S, Yadav G, Gandhi SG and Goswami A: Overlapping targets
exist between the Par-4 and miR-200c axis which regulate EMT and
proliferation of pancreatic cancer cells. Transl Oncol.
14:1008792021. View Article : Google Scholar
|
|
104
|
Pan H, Liu Y, Bao K, Wang Y, Zhang Y and
Zhou L: DYRK2 regulates epithelial-mesenchymal transition
restriction in pancreatic cancer liver metastasis by inhibiting
Twist. Digestion. Nov;19:2024.Epub ahead of print. View Article : Google Scholar
|
|
105
|
Gabitova-Cornell L, Surumbayeva A, Peri S,
Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman
TR, Francescone R, et al: Cholesterol pathway inhibition induces
TGF-β Signaling to promote basal differentiation in pancreatic
cancer. Cancer Cell. 38:567–583.e11. 2020. View Article : Google Scholar
|
|
106
|
Sun Y, Li D, Liu H, Huang Y, Meng F, Tang
J, Li Z and Xie W: PHF13 epigenetically activates TGFβ driven
epithelial to mesenchymal transition. Cell Death Dis. 13:4872022.
View Article : Google Scholar
|
|
107
|
Uddin MH, Al-Hallak MN, Philip PA, Chen H,
El-Rayes B and Azmi AS: Aberrant transcription factors in the
cancers of the pancreas. Semin Cancer Biol. 86:28–45. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhao Z, Yang W, Kong R, Zhang Y, Li L,
Song Z, Chen H, Luo Y, Zhang T, Cheng C, et al: circEIF3I
facilitates the recruitment of SMAD3 to early endosomes to promote
TGF-β signalling pathway-mediated activation of MMPs in pancreatic
cancer. Mol Cancer. 22:1522023. View Article : Google Scholar
|
|
109
|
Zhou K, Liu Y, Tang C and Zhu H:
Pancreatic cancer: Pathogenesis and clinical studies. MedComm
(2020). 6:e701622025. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y
and Zhao X: Tumor-stroma TGF-β1-THBS2 feedback circuit drives
pancreatic ductal adenocarcinoma progression via integrin
αvβ3/CD36-mediated activation of the MAPK pathway. Cancer Lett.
528:59–75. 2022. View Article : Google Scholar
|
|
111
|
Wang Z, Guo X, Li X, Wang J, Zhang N, Amin
B, Xu G and Zhu B: Cancer-associated fibroblast-derived MMP11
promotes tumor progression in pancreatic cancer. Cancer Sci.
116:643–655. 2025. View Article : Google Scholar :
|
|
112
|
Guo H, Zhao Z and Liu L: HIF-1α modulates
pancreatic cancer ECM proteins via the TGF-β1/Smad signaling
pathway introduction. Front Oncol. 15:15646552025. View Article : Google Scholar
|
|
113
|
Lee JE, Lee P, Yoon YC, Han BS, Ko S, Park
MS, Lee YJ, Kim SE, Cho YJ, Lim JH, et al: Vactosertib, TGF-β
receptor I inhibitor, augments the sensitization of the anti-cancer
activity of gemcitabine in pancreatic cancer. Biomed Pharmacother.
162:1147162023. View Article : Google Scholar
|
|
114
|
TGFβ promotes immune evasion to limit the
efficacy of Anti-PD-1/PD-L1. Cancer Discov. 8:OF102018. View Article : Google Scholar
|
|
115
|
Oronsky B, Cabrales P, Alizadeh B, Caroen
S, Stirn M, Williams J and Reid TR: TGF-β TGF-β: The apex predator
of immune checkpoints. Future Oncol. 19:2013–2015. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhou C, Zhu X, Liu N, Dong X, Zhang X,
Huang H, Tang Y, Liu S and Hu M: B-lymphoid tyrosine
kinase-mediated FAM83A phosphorylation elevates pancreatic
tumorigenesis through interacting with β-catenin. Signal Transduct
Target Ther. 8:662023. View Article : Google Scholar
|
|
117
|
Zhou C, Dong X, Li S, Xi Y, Liu Y, Qian X,
Song Z, Zhou L, Zhang R, Lyu H, et al: Serine/threonine/tyrosine
Kinase 1 drives pancreatic carcinogenesis via GSK3β
sequestration-mediated Wnt/β-catenin pathway hyperactivation.
Signal Transduct Target Ther. 10:2052025. View Article : Google Scholar
|
|
118
|
Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu
J, Liang C, Hua J, Zhao Y, Yu X and Shi S: Signaling pathways in
cancer-associated fibroblasts: Recent advances and future
perspectives. Cancer Commun (Lond). 43:3–41. 2023. View Article : Google Scholar :
|
|
119
|
Bailey P, Chang DK, Nones K, Johns AL,
Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC,
et al: Genomic analyses identify molecular subtypes of pancreatic
cancer. Nature. 531:47–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Rong Z, Xu J, Yang J, Wang W, Tang R,
Zhang Z, Tan Z, Meng Q, Hua J, Liu J, et al: CircRREB1 mediates
metabolic reprogramming and stemness maintenance to facilitate
pancreatic ductal adenocarcinoma progression. Cancer Res.
84:4246–4263. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Fang Z, Wu Z, Yu C, Xie Q, Zeng L and Chen
R: EIF4E-mediated biogenesis of circPHF14 promotes the growth and
metastasis of pancreatic ductal adenocarcinoma via Wnt/β-catenin
pathway. Mol Cancer. 24:562025. View Article : Google Scholar
|
|
122
|
Zheng S, Lin J, Pang Z, Zhang H, Wang Y,
Ma L, Zhang H, Zhang X, Chen M, Zhang X, et al: Aberrant
cholesterol metabolism and Wnt/β-catenin signaling coalesce via
Frizzled5 in supporting cancer growth. Adv Sci (Weinh).
9:e22007502022. View Article : Google Scholar
|
|
123
|
Wang W, Shao F, Yang X, Wang J, Zhu R,
Yang Y, Zhao G, Guo D, Sun Y, Wang J, et al: METTL3 promotes tumour
development by decreasing APC expression mediated by APC mRNA
N6-methyladenosine-dependent YTHDF binding. Nat Commun.
12:38032021. View Article : Google Scholar
|
|
124
|
Fu X, Ma J, Ma F, Guo S, Wang X, Li Y,
Tang Y, Qi J, Zhang W and Ye L: MISP-mediated enhancement of
pancreatic cancer growth through the Wnt/β-catenin signaling
pathway is suppressed by Fisetin. Biochim Biophys Acta Mol Basis
Dis. 1871:1675152025. View Article : Google Scholar
|
|
125
|
Roy SK, Ma Y, Lam BQ, Shrivastava A,
Srivastav S, Shankar S and Srivastava RK: Riluzole regulates
pancreatic cancer cell metabolism by suppressing the Wnt-β-catenin
pathway. Sci Rep. 12:110622022. View Article : Google Scholar
|
|
126
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Sivakumar S, de Santiago I, Chlon L and
Markowetz F: Master regulators of oncogenic KRAS response in
pancreatic cancer: An integrative network biology analysis. PLoS
Med. 14:e10022232017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Kumar G, Farooqui M and Rao CV: Role of
dietary cancer-preventive phytochemicals in pancreatic cancer stem
cells. Curr Pharmacol Rep. 4:326–335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Pan X, Zhou J, Xiao Q, Fujiwara K, Zhang
M, Mo G, Gong W and Zheng L: Cancer-associated fibroblast
heterogeneity is associated with organ-specific metastasis in
pancreatic ductal adenocarcinoma. J Hematol Oncol. 14:1842021.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zhu S, Xu H, Chen R, Shen Q, Yang D, Peng
H, Tong J and Fu Q: DNA methylation and miR-92a-3p-mediated
repression of HIP1R promotes pancreatic cancer progression by
activating the PI3K/AKT pathway. J Cell Mol Med. 27:788–802. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Lomberk G, Blum Y, Nicolle R, Nair A,
Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, et al:
Distinct epigenetic landscapes underlie the pathobiology of
pancreatic cancer subtypes. Nat Commun. 9:19782018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Silverman BR and Shi J: Alterations of
epigenetic regulators in pancreatic cancer and their clinical
implications. Int J Mol Sci. 17:21382016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Xie VK, Li Z, Yan Y, Jia Z, Zuo X, Ju Z,
Wang J, Du J, Xie D, Xie K and Wei D: DNA-Methyltransferase 1
induces dedifferentiation of pancreatic cancer cells through
silencing of Krüppel-like factor 4 expression. Clin Cancer Res.
23:5585–5597. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Hong L, Sun G, Peng L, Tu Y, Wan Z, Xiong
H, Li Y and Xiao W: The interaction between miR-148a and DNMT1
suppresses cell migration and invasion by reactivating tumor
suppressor genes in pancreatic cancer. Oncol Rep. 40:2916–2925.
2018.PubMed/NCBI
|
|
135
|
Xiao M, Liang X, Yan Z, Chen J, Zhu Y, Xie
Y, Li Y, Li X, Gao Q, Feng F, et al: A DNA-methylation-driven genes
based prognostic signature reveals immune microenvironment in
pancreatic cancer. Front Immunol. 13:8039622022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lo EKW, Idrizi A, Tryggvadottir R, Zhou W,
Hou W, Ji H, Cahan P and Feinberg AP: DNA methylation memory of
pancreatic acinar-ductal metaplasia transition state altering
Kras-downstream PI3K and Rho GTPase signaling in the absence of
Kras mutation. Genome Med. 17:322025. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Szymoński K, Lipiec E, Sofińska K,
Skirlińska-Nosek K, Czaja M, Seweryn S, Wilkosz N, Birarda G,
Piccirilli F, Vaccari L, et al: Variabilities in global DNA
methylation and β-sheet richness establish spectroscopic landscapes
among subtypes of pancreatic cancer. Eur J Nucl Med Mol Imaging.
50:1792–1810. 2023. View Article : Google Scholar
|
|
138
|
Lin Z, Chen Y, Lin Z, Chen C and Dong Y:
Overexpressing PRMT1 inhibits proliferation and invasion in
pancreatic cancer by inverse correlation of ZEB1. IUBMB Life.
70:1032–1039. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Wang Y, Hsu JM, Kang Y, Wei Y, Lee PC,
Chang SJ, Hsu YH, Hsu JL, Wang HL, Chang WC, et al: Oncogenic
functions of gli1 in pancreatic adenocarcinoma are supported by Its
PRMT1-mediated methylation. Cancer Res. 76:7049–7058. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ge L, Wang H, Xu X, Zhou Z, He J, Peng W,
Du F, Zhang Y, Gong A and Xu M: PRMT5 promotes
epithelial-mesenchymal transition via EGFR-β-catenin axis in
pancreatic cancer cells. J Cell Mol Med. 24:1969–1979. 2020.
View Article : Google Scholar :
|
|
141
|
Niu N, Lu P, Yang Y, He R, Zhang L, Shi J,
Wu J, Yang M, Zhang ZG, Wang LW, et al: Loss of Setd2 promotes
Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal
transition during pancreatic carcinogenesis. Gut. 69:715–726. 2020.
View Article : Google Scholar
|
|
142
|
Liu M, Shi Y, Hu Q, Qin Y, Ji S, Liu W,
Zhuo Q, Fan G, Ye Z, Song C, et al: SETD8 induces stemness and
epithelial-mesenchymal transition of pancreatic cancer cells by
regulating ROR1 expression. Acta Biochim Biophys Sin (Shanghai).
53:1614–1624. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Viotti M, Wilson C, McCleland M, Koeppen
H, Haley B, Jhunjhunwala S, Klijn C, Modrusan Z, Arnott D, Classon
M, et al: SUV420H2 is an epigenetic regulator of
epithelial/mesenchymal states in pancreatic cancer. J Cell Biol.
217:763–777. 2018. View Article : Google Scholar :
|
|
144
|
Wanna-Udom S, Terashima M, Suphakhong K,
Ishimura A, Takino T and Suzuki T: KDM2B is involved in the
epigenetic regulation of TGF-β-induced epithelial-mesenchymal
transition in lung and pancreatic cancer cell lines. J Biol Chem.
296:1002132021. View Article : Google Scholar
|
|
145
|
Quan M, Chen Z, Jiao F, Xiao X, Xia Q,
Chen J, Chao Q, Li Y, Gao Y, Yang H, et al: Lysine demethylase 2
(KDM2B) regulates hippo pathway via MOB1 to promote pancreatic
ductal adenocarcinoma (PDAC) progression. J Exp Clin Cancer Res.
39:132020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Dandawate P, Ghosh C, Palaniyandi K, Paul
S, Rawal S, Pradhan R, Sayed AAA, Choudhury S, Standing D,
Subramaniam D, et al: The histone demethylase KDM3A, increased in
human pancreatic tumors, regulates expression of DCLK1 and promotes
tumorigenesis in mice. Gastroenterology. 1571646–1659. (e11)2019.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Li S, Wu L, Wang Q, Li Y and Wang X: KDM4B
promotes epithelial-mesenchymal transition through up-regulation of
ZEB1 in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai).
47:997–1004. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Li H, Peng C, Zhu C, Nie S, Qian X, Shi Z,
Shi M, Liang Y, Ding X, Zhang S, et al: Hypoxia promotes the
metastasis of pancreatic cancer through regulating
NOX4/KDM5A-mediated histone methylation modification changes in a
HIF1A-independent manner. Clin Epigenetics. 13:182021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yi Z, Wei S, Jin L, Jeyarajan S, Yang J,
Gu Y, Kim HS, Schechter S, Lu S, Paulsen MT, et al: KDM6A regulates
cell plasticity and pancreatic cancer progression by noncanonical
activin pathway. Cell Mol Gastroenterol Hepatol. 13:643–667. 2022.
View Article : Google Scholar :
|
|
150
|
Zhong Z, Harmston N, Wood KC, Madan B and
Virshup DM: A p300/GATA6 axis determines differentiation and Wnt
dependency in pancreatic cancer models. J Clin Invest.
132:e1563052022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Martinelli P, Carrillo-de Santa Pau E, Cox
T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E,
Ghaneh P, Malats N, et al: GATA6 regulates EMT and tumour
dissemination, and is a marker of response to adjuvant chemotherapy
in pancreatic cancer. Gut. 66:1665–1676. 2017. View Article : Google Scholar :
|
|
152
|
Mizuguchi Y, Specht S, Lunz JG III, Isse
K, Corbitt N, Takizawa T and Demetris AJ: Cooperation of p300 and
PCAF in the control of microRNA 200c/141 transcription and
epithelial characteristics. PLoS One. 7:e324492012. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
von Burstin J, Eser S, Paul MC, Seidler B,
Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, et
al: E-cadherin regulates metastasis of pancreatic cancer in vivo
and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
Gastroenterology. 137:361–371. e1–e5. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Aghdassi A, Sendler M, Guenther A, Mayerle
J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, Lerch MM and
Weiss FU: Recruitment of histone deacetylases HDAC1 and HDAC2 by
the transcriptional repressor ZEB1 downregulates E-cadherin
expression in pancreatic cancer. Gut. 61:439–448. 2012. View Article : Google Scholar
|
|
155
|
Wauters E, Sanchez-Arévalo Lobo VJ, Pinho
AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN,
Sutherland RL, et al: Sirtuin-1 regulates acinar-to-ductal
metaplasia and supports cancer cell viability in pancreatic cancer.
Cancer Res. 73:2357–2367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Chen J, Xu H, Zou X, Wang J, Zhu Y, Chen
H, Shen B, Deng X, Zhou A, Chin YE, et al: Snail recruits Ring1B to
mediate transcriptional repression and cell migration in pancreatic
cancer cells. Cancer Res. 74:4353–4363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Guo S, Xu X, Tang Y, Zhang C, Li J, Ouyang
Y, Ju J, Bie P and Wang H: miR-15a inhibits cell proliferation and
epithelial to mesenchymal transition in pancreatic ductal
adenocarcinoma by down-regulating Bmi-1 expression. Cancer Lett.
344:40–46. 2014. View Article : Google Scholar
|
|
158
|
Ning Z, Wang A, Liang J, Xie Y, Liu J, Yan
Q and Wang Z: USP22 promotes epithelial-mesenchymal transition via
the FAK pathway in pancreatic cancer cells. Oncol Rep.
32:1451–1458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Chen L, Xu Z, Li Q, Feng Q, Zheng C, Du Y,
Yuan R and Peng X: USP28 facilitates pancreatic cancer progression
through activation of Wnt/β-catenin pathway via stabilising FOXM1.
Cell Death Dis. 12:8872021. View Article : Google Scholar
|
|
160
|
Zhuo W, Zeng Z, Hu Y, Hu P, Han S, Wang D,
Wang F, Zhao Y, Huang Y, Wang J, et al: Metabolic stress-induced
reciprocal loop of long noncoding RNA ZFAS1 and ZEB1 promotes
epithelial-mesenchymal transition and metastasis of pancreatic
cancer cells. Cancer Sci. 114:3623–3635. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
He Z, Wang J, Zhu C, Xu J, Chen P, Jiang
X, Chen Y, Jiang J and Sun C: Exosome-derived FGD5-AS1 promotes
tumor-associated macrophage M2 polarization-mediated pancreatic
cancer cell proliferation and metastasis. Cancer Lett.
548:2157512022. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Huang X, Pan L, Zuo Z, Li M, Zeng L, Li R,
Ye Y, Zhang J, Wu G, Bai R, et al: LINC00842 inactivates
transcription co-regulator PGC-1α to promote pancreatic cancer
malignancy through metabolic remodelling. Nat Commun. 12:38302021.
View Article : Google Scholar
|
|
163
|
Hu Y, Wang F, Xu F, Fang K, Fang Z, Shuai
X, Cai K, Chen J, Hu P, Chen D, et al: A reciprocal feedback of Myc
and lncRNA MTSS1-AS contributes to extracellular acidity-promoted
metastasis of pancreatic cancer. Theranostics. 10:10120–10140.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
He Y, Yue H, Cheng Y, Ding Z, Xu Z, Lv C,
Wang Z, Wang J, Yin C, Hao H and Chen C: ALKBH5-mediated
m6A demethylation of KCNK15-AS1 inhibits pancreatic
cancer progression via regulating KCNK15 and PTEN/AKT signaling.
Cell Death Dis. 12:11212021. View Article : Google Scholar
|
|
165
|
Ji Y, Feng G, Hou Y, Yu Y, Wang R and Yuan
H: Long noncoding RNA MEG3 decreases the growth of head and neck
squamous cell carcinoma by regulating the expression of miR-421 and
E-cadherin. Cancer Med. 9:3954–3963. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Gu X, Li J, Zuo X, Chen K, Wan G, Deng LL,
Zhao W and Lu C: The long noncoding RNA MEG3 retains
Epithelial-mesenchymal transition by sponging miR-146b-5p to
regulate SLFN5 expression in breast cancer cells. J Immunol Res.
2022:18241662022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Zhang KD, Hu B, Cen G, Yang YH, Chen WW,
Guo ZY, Wang XF, Zhao Q and Qiu ZJ: MiR-301a transcriptionally
activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal
transition by targeting TP63 in pancreatic cancer. World J
Gastroenterol. 26:2349–2373. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Guo C, Liu J, Zhou Q, Song J, Zhang Z, Li
Z, Wang G, Yuan W and Sun Z: Exosomal noncoding RNAs and tumor drug
resistance. Cancer Res. 80:4307–4313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Xiong Q, Zhang Y, Xu Y, Yang Y, Zhang Z,
Zhou Y, Zhang S, Zhou L, Wan X, Yang X, et al: tiRNA-Val-CAC-2
interacts with FUBP1 to promote pancreatic cancer metastasis by
activating c-MYC transcription. Oncogene. 43:1274–1287. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Hong E, Park S, Ooshima A, Hong CP, Park
J, Heo JS, Lee S, An H, Kang JM, Park SH, et al: Inhibition of
TGF-β signalling in combination with nal-IRI plus
5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival
in pancreatic tumour mouse models. Sci Rep. 10:29352020. View Article : Google Scholar
|
|
171
|
Chen K, Cheng L, Qian W, Jiang Z, Sun L,
Zhao Y, Zhou Y, Zhao L, Wang P, Duan W, et al: Itraconazole
inhibits invasion and migration of pancreatic cancer cells by
suppressing TGF-β/SMAD2/3 signaling. Oncol Rep. 39:1573–1582.
2018.PubMed/NCBI
|
|
172
|
Sezer G, Onses MS, Sakir M, Sahin F,
Çamdal A, Sezer Z, Inal A and Ciftci Z: Indomethacin prevents
TGF-β-induced epithelial-to-mesenchymal transition in pancreatic
cancer cells; evidence by Raman spectroscopy. Spectrochim Acta A
Mol Biomol Spectrosc. 280:1214932022. View Article : Google Scholar
|
|
173
|
Cheng P, Chen Y, He TL, Wang C, Guo SW, Hu
H, Ni CM, Jin G and Zhang YJ: Menin coordinates C/EBPβ-mediated
TGF-β signaling for epithelial-mesenchymal transition and growth
inhibition in pancreatic cancer. Mol Ther Nucleic Acids.
18:155–165. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Ungefroren H, Christl J, Eiden C, Wellner
UF, Lehnert H and Marquardt JU: Autocrine TGFβ1 opposes exogenous
TGFβ1-induced cell migration and growth arrest through sustainment
of a feed-forward loop involving MEK-ERK signaling. Cancers
(Basel). 13. pp. 13572021, View Article : Google Scholar
|
|
175
|
Zhu X, Zhang T, Zhang Y, Chen H, Shen J,
Jin X, Wei J, Zhang E, Xiao M, Fan Y, et al: A super-enhancer
controls TGF-β signaling in pancreatic cancer through
downregulation of TGFBR2. Cell Signal. 66:1094702020. View Article : Google Scholar
|
|
176
|
Cheng CS, Wu Y, Jin JB, Xu JY, Yang PW,
Zhu WH, Zheng L and Chen JX: Cynanchum paniculatum(Bunge) Kitag. ex
H.Hara inhibits pancreatic cancer progression by inducing
caspase-dependent apoptosis and suppressing TGF-β-mediated
epithelial-mesenchymal transition. Front Pharmacol. 15:12843712024.
View Article : Google Scholar
|
|
177
|
Zhao L, Chen G, Li D, Wang K, Schaefer M,
Herr I and Yan B: Baicalein disrupts TGF-β-induced EMT in
pancreatic cancer by FTO-dependent m6A demethylation of ZEB1.
Biochim Biophys Acta Mol Cell Res. 1872:1199692025. View Article : Google Scholar
|
|
178
|
Zhang Z, Auyeung KK, Sze SC, Zhang S, Yung
KK and Ko JK: The dual roles of calycosin in growth inhibition and
metastatic progression during pancreatic cancer development: A
'TGF-β paradox'. Phytomedicine. 68:1531772020. View Article : Google Scholar
|
|
179
|
Liu QQ, Chen K, Ye Q, Jiang XH and Sun YW:
Oridonin inhibits pancreatic cancer cell migration and
epithelial-mesenchymal transition by suppressing Wnt/β-catenin
signaling pathway. Cancer Cell Int. 16:572016. View Article : Google Scholar
|
|
180
|
Zhou C, Li J, Qian W, Yue Y, Xiao Y, Qin
T, Ma Q and Li X: Huaier extract restrains pancreatic cancer by
suppressing Wnt/β-catenin pathway. Biomed Pharmacother.
127:1101262020. View Article : Google Scholar
|
|
181
|
Kim JH, Hwang S, Lee JH, Im SS and Son J:
Vitamin C suppresses pancreatic carcinogenesis through the
inhibition of both glucose metabolism and Wnt signaling. Int J Mol
Sci. 23:122492022. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Guo Q and Qin W: DKK3 blocked
translocation of β-catenin/EMT induced by hypoxia and improved
gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell. J
Cell Mol Med. 19:2832–2841. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Douchi D, Ohtsuka H, Ariake K, Masuda K,
Kawasaki S, Kawaguchi K, Fukase K, Oikawa M, Motoi F, Naitoh T, et
al: Silencing of LRRFIP1 reverses the epithelial-mesenchymal
transition via inhibition of the Wnt/β-catenin signaling pathway.
Cancer Lett. 365:132–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Li F, Dai L and Niu J: GPX2 silencing
relieves epithelial-mesenchymal transition, invasion, and
metastasis in pancreatic cancer by downregulating Wnt pathway. J
Cell Physiol. 235:7780–7790. 2020. View Article : Google Scholar
|
|
185
|
Qin C, Li T, Wang Y, Zhao B, Li Z, Li T,
Yang X, Zhao Y and Wang W: CHRNB2 represses pancreatic cancer
migration and invasion via inhibiting β-catenin pathway. Cancer
Cell Int. 22:3402022. View Article : Google Scholar
|
|
186
|
Wu J, Li H, Shi M, Zhu Y, Ma Y, Zhong Y,
Xiong C, Chen H and Peng C: TET1-mediated DNA hydroxymethylation
activates inhibitors of the Wnt/β-catenin signaling pathway to
suppress EMT in pancreatic tumor cells. J Exp Clin Cancer Res.
38:3482019. View Article : Google Scholar
|
|
187
|
Cao L, Xiao X, Lei J, Duan W, Ma Q and Li
W: Curcumin inhibits hypoxia-induced epithelial-mesenchymal
transition in pancreatic cancer cells via suppression of the
hedgehog signaling pathway. Oncol Rep. 35:3728–3734. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Fu J, Shrivastava A, Shrivastava SK,
Srivastava RK and Shankar S: Triacetyl resveratrol upregulates
miRNA-200 and suppresses the Shh pathway in pancreatic cancer: A
potential therapeutic agent. Int J Oncol. 54:1306–1316.
2019.PubMed/NCBI
|
|
189
|
Verma RK, Yu W, Shrivastava A, Shankar S
and Srivastava RK: α-Mangostin-encapsulated PLGA nanoparticles
inhibit pancreatic carcinogenesis by targeting cancer stem cells in
human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
Sci Rep. 6:327432016. View Article : Google Scholar
|
|
190
|
Ma Y, Yu W, Shrivastava A, Srivastava RK
and Shankar S: Inhibition of pancreatic cancer stem cell
characteristics by α-Mangostin: Molecular mechanisms involving
Sonic hedgehog and Nanog. J Cell Mol Med. 23:2719–2730. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Bai Y, Chen B, Hong W, Liang Y, Zhou M and
Zhou L: Sedum sarmentosum Bunge extract induces apoptosis and
inhibits proliferation in pancreatic cancer cells via the hedgehog
signaling pathway. Oncol Rep. 35:2775–2784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Roy Chaudhuri T, Lin Q, Stachowiak EK,
Rosario SR, Spernyak JA, Ma WW, Stachowiak MK, Greene MK, Quinn GP,
McDade SS, et al: Dual-hit strategy for therapeutic targeting of
pancreatic cancer in patient-derived xenograft tumors. Clin Cancer
Res. 30:1367–1381. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He
ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, et al: Alisertib induces
cell cycle arrest and autophagy and suppresses
epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and
sirtuin 1-mediated signaling pathways in human pancreatic cancer
cells. Drug Des Devel Ther. 9:575–601. 2015.PubMed/NCBI
|
|
194
|
Sun L, Cao J, Chen K, Cheng L, Zhou C, Yan
B, Qian W, Li J, Duan W, Ma J, et al: Betulinic acid inhibits
stemness and EMT of pancreatic cancer cells via activation of AMPK
signaling. Int J Oncol. 54:98–110. 2019.
|
|
195
|
Liu J, Song N, Huang Y and Chen Y: Irisin
inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway.
Sci Rep. 8:152472018. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He
ZX, Zhang X, Wang D, Yang YX, Yang T, et al: Plumbagin induces cell
cycle arrest and autophagy and suppresses epithelial to mesenchymal
transition involving PI3K/Akt/mTOR-mediated pathway in human
pancreatic cancer cells. Drug Des Devel Ther. 9:537–560.
2015.PubMed/NCBI
|
|
197
|
Li Q, Yang Y, Lin X, Chu LT, Chen H, Chen
L, Tang J and Zeng T: Regulation of pancreatic cancer cells by
suppressing KIN17 through the PI3K/AKT/mTOR signaling pathway.
Oncol Rep. 53:312025. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Tian Z, Tan Y, Lin X, Su M, Pan L, Lin L,
Ou G and Chen Y: Arsenic trioxide sensitizes pancreatic cancer
cells to gemcitabine through downregulation of the
TIMP1/PI3K/AKT/mTOR axis. Transl Res. 255:66–76. 2023. View Article : Google Scholar
|
|
199
|
Li W, Sun L, Lei J, Wu Z, Ma Q and Wang Z:
Curcumin inhibits pancreatic cancer cell invasion and EMT by
interfering with tumor-stromal crosstalk under hypoxic conditions
via the IL-6/ERK/NF-κB axis. Oncol Rep. 44:382–392. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Dai S, Zhang J, Huang S, Lou B, Fang B, Ye
T, Huang X, Chen B and Zhou M: HNRNPA2B1 regulates the
epithelial-mesenchymal transition in pancreatic cancer cells
through the ERK/snail signalling pathway. Cancer Cell Int.
17:122017. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Sun J, Chen L and Dong M: MiR-338-5p
inhibits EGF-induced EMT in pancreatic cancer cells by targeting
EGFR/ERK signaling. Front Oncol. 11:6164812021. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Ungefroren H, Konukiewitz B, Braun R,
Wellner UF, Lehnert H and Marquardt JU: TAp73 inhibits EMT and cell
migration in pancreatic cancer cells through promoting SMAD4
expression and SMAD4-dependent inhibition of ERK activation.
Cancers (Basel). 15. pp. 37912023, View Article : Google Scholar
|
|
203
|
Luan YZ, Wang CC, Yu CY, Chang YC, Sung WW
and Tsai MC: The therapeutic role of NPS-1034 in pancreatic ductal
adenocarcinoma as monotherapy and in combination with chemotherapy.
Int J Mol Sci. 25:69192024. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Yao H, Ren Y, Wu F, Cao L, Liu J, Yan M
and Li X: The discovery of a Novel AXL/triple angiokinase inhibitor
based on 6-chloro-substituted indolinone and side chain Methyl
substitution inhibiting pancreatic cancer growth and metastasis. J
Med Chem. 68:465–490. 2025. View Article : Google Scholar
|
|
205
|
Mekapogu AR, Xu Z, Pothula S, Perera C,
Pang T, Hosen SMZ, Damalanka V, Janetka J, Goldstein D, Pirola R,
et al: HGF/c-Met pathway inhibition combined with chemotherapy
increases cytotoxic T-cell infiltration and inhibits pancreatic
tumour growth and metastasis. Cancer Lett. 568:2162862023.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Zhao J, Liu X, Jin X, Dong T, Gao X, Wang
J, Li Y and Ma E: Riboflavin protects against pancreatic cancer
metastasis by targeting TGF-β receptor 1. Bioorg Chem.
146:1072742024. View Article : Google Scholar
|
|
207
|
Bu XN, Qiu C, Wang C and Jiang Z:
Inhibition of DACH1 activity by short hairpin RNA represses cell
proliferation and tumor invasion in pancreatic cancer. Oncol Rep.
36:745–754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Liu B, Wu S, Ma J, Yan S, Xiao Z, Wan L,
Zhang F, Shang M and Mao A: lncRNA GAS5 reverses EMT and tumor stem
cell-mediated gemcitabine resistance and metastasis by targeting
miR-221/SOCS3 in pancreatic cancer. Mol Ther Nucleic Acids.
13:472–482. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Chen S, Chen JZ, Zhang JQ, Chen HX, Qiu
FN, Yan ML, Tian YF, Peng CH, Shen BY, Chen YL, et al: Silencing of
long noncoding RNA LINC00958 prevents tumor initiation of
pancreatic cancer by acting as a sponge of microRNA-330-5p to
down-regulate PAX8. Cancer Lett. 446:49–61. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Zhou Y, Zhou X, Ben Q, Liu N, Wang J, Zhai
Y, Bao Y and Zhou L: GATA6-AS1 suppresses epithelial-mesenchymal
transition of pancreatic cancer under hypoxia through regulating
SNAI1 mRNA stability. J Transl Med. 21:8822023. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Huang R, Yang L, Zhang Z, Liu X, Fei Y,
Tong WM, Niu Y and Liang Z: RNA m6A Demethylase ALKBH5
protects against pancreatic ductal adenocarcinoma via targeting
regulators of iron metabolism. Front Cell Dev Biol. 9:7242822021.
View Article : Google Scholar
|
|
212
|
Schiedlauske K, Deipenbrock A, Pflieger M,
Hamacher A, Hänsel J, Kassack MU, Kurz T and Teusch NE: Novel
histone deacetylase (HDAC) inhibitor induces apoptosis and
suppresses invasion via E-cadherin upregulation in pancreatic
ductal adenocarcinoma (PDAC). Pharmaceuticals (Basel). 17. pp.
7522024, View Article : Google Scholar
|
|
213
|
Jia Y, Li J, Mei W, Zhang H, Wang Z, Xie
X, Gao C, Xu X and Li F: Pan-HDAC inhibitor LAQ824 inhibits the
progression of pancreatic ductal adenocarcinoma and suppresses
immune escape by promoting antigen presentation. Int
Immunopharmacol. 154:1145282025. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Mody HR, Hung SW, AlSaggar M, Griffin J
and Govindarajan R: I n h ibit ion of S -Adenosyl met h ion i ne -D
ep endent Methyltransferase Attenuates TGFβ1-induced EMT and
metastasis in pancreatic cancer: Putative roles of miR-663a and
miR-4787-5p. Mol Cancer Res. 14:1124–1135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Mody HR, Hung SW, Pathak RK, Griffin J,
Cruz-Monserrate Z and Govindarajan R: miR-202 diminishes TGFβ
receptors and attenuates TGFβ1-induced EMT in pancreatic cancer.
Mol Cancer Res. 15:1029–1039. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Gui Z, Luo F, Yang Y, Shen C, Li S and Xu
J: Oridonin inhibition and miR-200b-3p /ZEB1 axis in human
pancreatic cancer. Int J Oncol. 50:111–120. 2017. View Article : Google Scholar
|
|
217
|
Garg R, Melstrom L, Chen J, He C and Goel
A: Targeting FTO suppresses pancreatic carcinogenesis via
regulating stem cell maintenance and EMT pathway. Cancers (Basel).
14. pp. 59192022, View Article : Google Scholar
|
|
218
|
Kim SH, Ryu KJ, Hong KS, Kim H, Han H, Kim
M, Kim T, Ok DW, Yang JW, Hwangbo C, et al: ERK3 increases snail
protein stability by inhibiting FBXO11-mediated snail
ubiquitination. Cancers (Basel). 16. pp. 1052023, View Article : Google Scholar
|
|
219
|
Hu H, Wang Y, Ding X, He Y, Lu Z, Wu P,
Tian L, Yuan H, Liu D, Shi G, et al: Long non-coding RNA
XLOC_000647 suppresses progression of pancreatic cancer and
decreases epithelial-mesenchymal transition-induced cell invasion
by down-regulating NLRP3. Mol Cancer. 17:182018. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Li C, Cai J, Liu W, Gao Z and Li G:
Downregulation of circ-STK39 suppresses pancreatic cancer
progression by sponging mir-140-3p and regulating TRAM2-mediated
epithelial-mesenchymal transition. Apoptosis. 28:1024–1034. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Cao T, Hong L, Yu D, Shen J, Jiang L, Hu N
and He S: Circular RNA circTMEM59 inhibits progression of
pancreatic ductal adenocarcinoma by targeting miR-147b/SOCS1: An in
vitro study. Heliyon. 10:e244022024. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Su X, Lai T, Tao Y, Zhang Y, Zhao C, Zhou
J, Chen E, Zhu M, Zhang S, Wang B, et al: miR-33a-3p regulates
METTL3-mediated AREG stability and alters EMT to inhibit pancreatic
cancer invasion and metastasis. Sci Rep. 13:135872023. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Edderkaoui M, Chheda C, Soufi B, Zayou F,
Hu RW, Ramanujan VK, Pan X, Boros LG, Tajbakhsh J, Madhav A, et al:
An inhibitor of GSK3B and HDACs kills pancreatic cancer cells and
slows pancreatic tumor growth and metastasis in mice.
Gastroenterology. 1551985–1998. (e5)2018. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Li Y, Zheng Y, Xu S, Hu H, Peng L, Zhu J
and Wu M: The nanobody targeting PD-L1 and CXCR4 counteracts
pancreatic stellate cell-mediated tumour progression by disrupting
tumour microenvironment. Int Immunopharmacol. 132:1119442024.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Li Y, Hong J, Jung BK, Oh E and Yun CO:
Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes
chemoresistance of desmoplastic tumor through degradation of ECM
and inhibition of EMT. Cancer Lett. 459:15–29. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Fujisawa T, Tsuchiya T, Kato M, Mizuide M,
Takakura K, Nishimura M, Kutsumi H, Matsuda Y, Arai T, Ryozawa S,
et al: STNM01, the RNA oligonucleotide targeting carbohydrate
sulfotransferase 15, as second-line therapy for
chemotherapy-refractory patients with unresectable pancreatic
cancer: An open label, phase I/IIa trial. EClinicalMedicine.
55:1017312022. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Jiang Z, Zhou C, Cheng L, Yan B, Chen K,
Chen X, Zong L, Lei J, Duan W, Xu Q, et al: Inhibiting YAP
expression suppresses pancreatic cancer progression by disrupting
tumor-stromal interactions. J Exp Clin Cancer Res. 37:692018.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Ireland L, Luckett T, Schmid MC and Mielgo
A: Blockade of stromal Gas6 alters cancer cell plasticity,
activates NK Cells, and inhibits pancreatic cancer metastasis.
Front Immunol. 11:2972020. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Shen L, Li J, Liu Q, Das M, Song W, Zhang
X, Tiruthani K, Dorosheva O, Hu H, Lai SK, et al: Nano-trapping
CXCL13 reduces regulatory B cells in tumor microenvironment and
inhibits tumor growth. J Control Release. 343:303–313. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Pothula SP, Xu Z, Goldstein D, Biankin AV,
Pirola RC, Wilson JS and Apte MV: Hepatocyte growth factor
inhibition: A novel therapeutic approach in pancreatic cancer. Br J
Cancer. 114:269–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Mondal G, Almawash S, Chaudhary AK and
Mahato RI: EGFR-Targeted cationic polymeric mixed micelles for
codelivery of gemcitabine and miR-205 for treating advanced
pancreatic cancer. Mol Pharm. 14:3121–3133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Cao ZQ, Wang XX, Lu L, Xu JW, Li XB, Zhang
GR, Ma ZJ, Shi AC, Wang Y and Song YJ: β-Sitosterol and gemcitabine
exhibit synergistic Anti-pancreatic cancer activity by modulating
apoptosis and inhibiting Epithelial-mesenchymal transition by
deactivating Akt/GSK-3β signaling. Front Pharmacol. 9:15252019.
View Article : Google Scholar
|
|
233
|
Wei R, Penso NEC, Hackman RM, Wang Y and
Mackenzie GG: Epigallocatechin-3-Gallate (EGCG) suppresses
pancreatic cancer cell growth, invasion, and migration partly
through the inhibition of akt pathway and Epithelial-mesenchymal
transition: Enhanced efficacy when combined with gemcitabine.
Nutrients. 11:18562019. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Li M, Wang X, Chen X, Hong J, Du Y and
Song D: GK921, a transglutaminase inhibitor, strengthens the
antitumor effect of cisplatin on pancreatic cancer cells by
inhibiting epithelial-to-mesenchymal transition. Biochim Biophys
Acta Mol Basis Dis. 1870:1669252024. View Article : Google Scholar
|
|
235
|
Jin H, Zhao Y, Zhang S, Yang J, Zhang X
and Ma S: Hyperthermia inhibits the motility of
gemcitabine-resistant pancreatic cancer PANC-1 cells through the
inhibition of epithelial-mesenchymal transition. Mol Med Rep.
17:7274–7280. 2018.PubMed/NCBI
|
|
236
|
Momeny M, Alishahi Z, Eyvani H, Esmaeili
F, Zaghal A, Ghaffari P, Tavakkoly-Bazzaz J, Alimoghaddam K,
Ghavamzadeh A and Ghaffari SH: Anti-tumor activity of cediranib, a
pan-vascular endothelial growth factor receptor inhibitor, in
pancreatic ductal adenocarcinoma cells. Cell Oncol (Dordr).
43:81–93. 2020. View Article : Google Scholar
|
|
237
|
Mondal SK, Jinka S, Pal K, Nelli S, Dutta
SK, Wang E, Ahmad A, AlKharfy KM, Mukhopadhyay D and Banerjee R:
Glucocorticoid Receptor-targeted liposomal codelivery of lipophilic
drug and Anti-Hsp90 gene: Strategy to Induce Drug-sensitivity,
EMT-Reversal, and reduced malignancy in aggressive tumors. Mol
Pharm. 13:2507–2523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Guo D, Sheng K, Zhang Q, Li P, Sun H, Wang
Y, Lyu X, Jia Y, Wang C, Wu J, et al: Single-cell transcriptomic
analysis reveals the landscape of epithelial-mesenchymal transition
molecular heterogeneity in esophageal squamous cell carcinoma.
Cancer Lett. 587:2167232024. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Buchholz M, Lausser L, Schenk M, Earl J,
Lawlor RT, Scarpa A, Sanjuanbenito A, Carrato A, Malats N, Tjaden
C, et al: Combined analysis of a serum mRNA/miRNA marker signature
and CA 19-9 for timely and accurate diagnosis of recurrence after
resection of pancreatic ductal adenocarcinoma: A prospective
multicenter cohort study. United European Gastroenterol J.
13:353–363. 2025. View Article : Google Scholar :
|
|
240
|
Teixeira AF, Ten Dijke P and Zhu HJ:
On-Target Anti-TGF-β therapies are not succeeding in clinical
cancer treatments: What are remaining challenges? Front Cell Dev
Biol. 8:6052020. View Article : Google Scholar
|
|
241
|
Chen Q, Wang H, Liu Q and Luo C: CTHRC1: A
key player in colorectal cancer progression and immune evasion.
Front Immunol. 16:15796612025. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Gu M, Liu Y, Xin P, Guo W, Zhao Z, Yang X,
Ma R, Jiao T and Zheng W: Fundamental insights and molecular
interactions in pancreatic cancer: Pathways to therapeutic
approaches. Cancer Lett. 588:2167382024. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Zhu SL, Qi M, Chen MT, Lin JP, Huang HF,
Deng LJ and Zhou XW: A novel DDIT3 activator dehydroevodiamine
effectively inhibits tumor growth and tumor cell stemness in
pancreatic cancer. Phytomedicine. 128:1553772024. View Article : Google Scholar : PubMed/NCBI
|
